A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.

ABSTRACT: Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman's disease, polyarticular and systemic juvenile idiopathic arthritis, and, most recently, giant cell arteritis as well as for the treatment of chimeric antigen receptor T cell therapy-induced cytokine release syndrome. The global clinical development program for TCZ provides a wealth of clinical data on intravenous TCZ, and more recent studies in patients with RA have provided evidence characterizing the role of intravenous TCZ as monotherapy in early disease and led to the introduction of a subcutaneous formulation of TCZ. In addition, recently published open-label extension and observational studies continue to sup

SUBMITTER: Rubbert-Roth A 

PROVIDER: S-EPMC5935615 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature